GTSM:6446

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

PharmaEssentia Corporation engages in the research, development, production, and sale of therapeutic products for the treatment of human diseases. More Details


Snowflake Analysis

Excellent balance sheet with high growth potential.

Share Price & News

How has PharmaEssentia's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6446 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 6446's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-0.9%

6446

-0.3%

TW Biotechs

2.0%

TW Market


1 Year Return

-20.3%

6446

22.9%

TW Biotechs

31.2%

TW Market

Return vs Industry: 6446 underperformed the TW Biotechs industry which returned 22.9% over the past year.

Return vs Market: 6446 underperformed the TW Market which returned 31.2% over the past year.


Shareholder returns

6446IndustryMarket
7 Day-0.9%-0.3%2.0%
30 Day-4.0%-6.1%10.6%
90 Day13.6%-0.3%22.8%
1 Year-20.3%-20.3%23.3%22.9%35.8%31.2%
3 Year-40.0%-40.0%-18.1%-19.5%58.3%40.5%
5 Year-47.7%-47.7%-51.3%-51.7%133.0%92.1%

Long-Term Price Volatility Vs. Market

How volatile is PharmaEssentia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is PharmaEssentia undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 6446 (NT$90.8) is trading below our estimate of fair value (NT$417.47)

Significantly Below Fair Value: 6446 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 6446 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 6446 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6446's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6446 is good value based on its PB Ratio (4x) compared to the TW Biotechs industry average (4.8x).


Next Steps

Future Growth

How is PharmaEssentia forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

90.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6446 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).

Earnings vs Market: 6446 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 6446's is expected to become profitable in the next 3 years.

Revenue vs Market: 6446's revenue (95.9% per year) is forecast to grow faster than the TW market (11.2% per year).

High Growth Revenue: 6446's revenue (95.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6446's Return on Equity is forecast to be low in 3 years time (17.8%).


Next Steps

Past Performance

How has PharmaEssentia performed over the past 5 years?

-4.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6446 is currently unprofitable.

Growing Profit Margin: 6446 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6446 is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.

Accelerating Growth: Unable to compare 6446's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6446 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.4%).


Return on Equity

High ROE: 6446 has a negative Return on Equity (-24.09%), as it is currently unprofitable.


Next Steps

Financial Health

How is PharmaEssentia's financial position?


Financial Position Analysis

Short Term Liabilities: 6446's short term assets (NT$5.1B) exceed its short term liabilities (NT$897.8M).

Long Term Liabilities: 6446's short term assets (NT$5.1B) exceed its long term liabilities (NT$496.5M).


Debt to Equity History and Analysis

Debt Level: 6446's debt to equity ratio (1.6%) is considered satisfactory.

Reducing Debt: 6446's debt to equity ratio has reduced from 12.4% to 1.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6446 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 6446 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is PharmaEssentia current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6446's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6446's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6446's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6446's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6446's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Ko-Chung Lin

4yrs

Tenure

Mr. Ko-Chung Lin, Ph.D., is the Founder & Chief Strategy Officer of PharmaEssentia Corporation and has been its Chief Executive Officer since January 01, 2017. Mr. Lin served as Managing Director of Global...


Leadership Team

NamePositionTenureCompensationOwnership
Ching-Leou Teng
Chairman & Chief Pharmaceutical Officerno datano datano data
Ko-Chung Lin
Founder4yrsno datano data
Chan-Kou Hwang
President5.67yrsno datano data
Snow Chang
Accounting Manager & Senior Manager of Finance5.25yrsno datano data
Albert Qin
Chief Medical Officer4yrsno datano data
Narihisa Miyachi
Head of Japan Medical Affairs2.5yrsno datano data
Yen-Tung Luan
Chief Operating Officer of Taichung Plant2.5yrsno datano data
Raymond W. Urbanski
Head of Clinical Development & Medical Affairs for U.S. Subsidiary0.25yrno datano data

4.0yrs

Average Tenure

Experienced Management: 6446's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ching-Leou Teng
Chairman & Chief Pharmaceutical Officerno datano datano data
Chan-Kou Hwang
President5.67yrsno datano data
Patrick Yang
Independent Director6.83yrsno datano data
Chao-Ho Chen
Director11.58yrsno datano data
Tian Chang
Director14.58yrsno datano data
Jinn-Der Chang
Independent Director6.83yrsno datano data
Lung-Chih Yu
Director14.58yrsno datano data
Shi-Ying Hsu
Director8.33yrsno datano data
Ben-Yuan Chen
Director14.58yrsno datano data
Jien-Heh Tien
Independent Director2.58yrsno datano data
Hui-Ping Wang
Director1yrno datano data

7.6yrs

Average Tenure

Experienced Board: 6446's board of directors are considered experienced (7.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.1%.


Top Shareholders

Company Information

PharmaEssentia Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PharmaEssentia Corporation
  • Ticker: 6446
  • Exchange: GTSM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$24.024b
  • Shares outstanding: 263.42m
  • Website: https://www.pharmaessentia.com

Location

  • PharmaEssentia Corporation
  • No. 3, park Street
  • 2nd Floor-5
  • Taipei
  • 115
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
6446GTSM (Taipei Exchange)YesCommon SharesTWTWDMar 2014

Biography

PharmaEssentia Corporation engages in the research, development, production, and sale of therapeutic products for the treatment of human diseases. Its products include ropeginterferon alfa-2b that is used ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/26 17:20
End of Day Share Price2021/01/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.